Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Following closely was ARK’s investment in Tempus AI Inc (TEM), where the firm bought 158,051 shares across its ARKK and ARKG ETFs, totaling $8,833,470. This purchase continues a recent trend of ARK ...

This marks the second FDA-cleared ECG-AI device in Tempus’ cardiovascular product suite, following its previously cleared Tempus ECG-AF solution. The new software analyzes resting, non-ambulatory ...

Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company also expects adjusted EBITDA ...

Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the ...

AI could inject an additional $461 billion into the healthcare sector by 2035, according to Accenture, as it races past the $2.26 trillion mark. This shift isn't just about diagnostics or ...

Key Takeaways Tempus AI stock shows 15–32% upside potential based on analyst forecasts.The company leads in using artificial ...

One of Wood's favorite AI stocks has been criticized by CNBC host Jim Cramer multiple times in 2025, including this week.

Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.